WALTHAM, Mass., Nov. 08, 2017 (GLOBE NEWSWIRE) — AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that management will participate in the Jefferies 2017 London Healthcare Conference on Wednesday, November 15th  at 2:40 p.m. GMT (9:40 a.m. ET).  To access the live webcast, please visit the Investors section of the company’s website at amagpharmadev.wpengine.com. A replay of the… More

More than one-third of study participants in Phase 2 Study were Cord Blood Registry® (CBR®) clients WALTHAM, Mass., Nov. 08, 2017 (GLOBE NEWSWIRE) — Cord Blood Registry (CBR) from AMAG Pharmaceuticals (Nasdaq:AMAG) today announced research recently published in the journal Stem Cells Translational Medicine found that children with cerebral palsy who received an infusion of… More

Data Shows Patients Treated with Feraheme® (ferumoxytol) were Less Likely to Develop Severe Hypophosphatemia Compared to Those Treated with a Comparator IV Iron WALTHAM, Mass., Nov. 06, 2017 (GLOBE NEWSWIRE) — AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced data related to the occurrence of hypophosphatemia following intravenous (IV) iron treatment at a podium presentation at the… More

Intrarosa® (prasterone) launch progressing well with nearly 2,000 prescribing physicians in the first 100 days since launch Conference call scheduled for 8:00 a.m. ET today WALTHAM, Mass., Nov. 02, 2017 (GLOBE NEWSWIRE) — AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today reported unaudited consolidated financial results for the quarter ended September 30, 2017 and updated its full year 2017 financial… More

WALTHAM, Mass., Oct. 19, 2017 (GLOBE NEWSWIRE) — AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that its third quarter 2017 financial results will be released on Thursday, November 2, 2017 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update… More

WALTHAM, Mass., Sept. 29, 2017 (GLOBE NEWSWIRE) — AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced the appointment of Tracy Palmer Berns as chief compliance officer effective immediately. She will report to Joseph Vittiglio, general counsel and senior vice president of legal affairs and quality. In her role at AMAG, Ms. Berns will be responsible for the… More

WALTHAM, Mass., Sept. 07, 2017 (GLOBE NEWSWIRE) — AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced the appointment of Laura Williams, M.D., M.P.H., as senior vice president of clinical development effective immediately.  She will report to Julie Krop, M.D., chief medical officer and senior vice president of clinical development and regulatory affairs at AMAG. Dr. Williams has… More

WALTHAM, Mass., Sept. 05, 2017 (GLOBE NEWSWIRE) — AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that company management will participate in the following investor conferences: Morgan Stanley Annual Global Health Care ConferenceMonday, September 11, 2017 at 3:40 p.m. ET Location: New York, NY Cantor Fitzgerald Global Healthcare ConferenceWednesday, September 27, 2017 at 2:50 p.m. ETLocation: New… More

Prescription Drug User Fee Act (PDUFA) Target Action Date of February 2, 2018 Established WALTHAM, Mass., Aug. 31, 2017 (GLOBE NEWSWIRE) — AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that the U.S. Food and Drug Administration (FDA) accepted its submission to broaden the existing label for Feraheme® (ferumoxytol) to include the treatment of all adults with… More

WALTHAM, Mass., Aug. 08, 2017 (GLOBE NEWSWIRE) — AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced the appointment of Oscar Sanchez as vice president of quality effective immediately.  He will report to Joseph Vittiglio, general counsel and senior vice president of legal affairs and quality. In his role at AMAG, Mr. Sanchez is responsible for creating and… More